Navigation Links
Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors. These data results were presented at the 2011 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and the 2011 American Association for Cancer Research (AACR) Annual Meeting and demonstrate that apricoxib potently inhibits the activity of COX-2 and COX-2 derived prostaglandin E2 (PGE2), which in turn mediates EMT and the associated progression and metastasis of solid tumors.

"Reversal of EMT may provide several clinical benefits to patients with non-small cell lung cancer and pancreatic cancer," stated Sara Zaknoen, M.D., chief medical officer, Tragara Pharmaceuticals, Inc. "Patients may experience longer survival due to effects of EMT reversal on metastases and the cancer stem cell, and benefit from the reversal of resistance to drugs such as erlotinib."

Tragara has completed two phase II clinical trials of apricoxib. Results from the APRiCOT-L trial, a biomarker-based, phase II, randomized, placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer, will be presented on June 6th at the ASCO meeting in Chicago. A second phase II study of apricoxib in combination with gemcitabine and erlotinib has completed enrollment and is currently being analyzed.

"COX-2 has been implicated in EMT, so we were gratified to see robust reversal of EMT resulting from apricoxib treatment in xenograft models of pancreatic, colon, and head and neck cancers," stated Francis Burrows, Ph.D., head of oncology biology, Tragara Pharmaceuticals, Inc.  "This effect was associated with profound inhibition of metastasis in orthotopic cancer models but, interestingly, apricoxib-mediated EMT re
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Ore. , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Accessory (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today ... voluntary recall to address a potential issue with ... used for the Axilla application of the SAM ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... RALEIGH, N.C., Aug. 22, 2011 BioDelivery Sciences International, ... the commercial launch and availability of ONSOLIS (fentanyl buccal ...   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is ... it will be marketed as BREAKYL) for the management ...
... SPRING, Md., Aug. 19, 2011 The U.S. Food ... treat Hodgkin lymphoma (HL) and a rare lymphoma known ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Lymphomas are cancers of ... combines an antibody and drug, allowing the antibody to ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3FDA Approves Adcetris to Treat Two Types of Lymphoma 2FDA Approves Adcetris to Treat Two Types of Lymphoma 3
(Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
(Date:9/1/2014)... Bioinformatics refers to an interdisciplinary ... and genetic data. A major part of this ... tools to generate and process useful biological data. ... computation. While bioinformatics simply makes use of computers ... related concepts, biological computation refers to the subfield ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
(Date:9/1/2014)... Diego, CA (PRWEB) September 01, 2014 ... daily regarding all the latest information from the FDA ... , The US FDA announced on August 28, that ... recalled (Class I) as the device may ... the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... Tobacco Recognized Nationally-, WASHINGTON, May 20 Michelle ... Youth Advocate of the Year,by the Campaign for Tobacco-Free ... is being honored at a gala in the nation,s,capital ... grant winner,three other regional winners and a group winner., ...
... Mich., May 19 Patrick Hendry lost,his career, home, wife ... seven years in and out of the hospital, trying every ... trying,electro-convulsive therapy, similar to shock therapy., "That was a ... and lost," said Hendry. "It,s difficult to figure out what ...
... WASHINGTON, May 20 Auriel Rolle-Polk, 17, of,Tallahassee, FL ... the,Year by the Campaign for Tobacco-Free Kids for her ... at a gala in the nation,s capital,on May 20 ... regional winners and a group winner., Auriel, a ...
... (Amex: CPD ) announced that the Company ... year 2008 ended March 31, 2008,prior to the ... Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets and ... wholesalers, distributors,drugstore chains and managed care providers., ...
... Ischemic injury to the bowel is a well known disease ... findings. A sudden drop in the colonic blood supply is ... of macrovascular mesenteric vein rarely causes ischemia of the bowel. ... by obstruction of the mesenteric and splenic veins. , ...
... This release is available in Spanish . , , A ... out a study on the psychological process that triggers the craving ... bases to determine the brain mechanisms that activate this state and ... from the Department of Personality, Evaluation and Psychological Treatment ...
Cached Medicine News:Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Man who Lost Everything Comes to Detroit to Spread Message of Hope 2Health News:Campaign for Tobacco-Free Kids Honors Auriel Rolle-Polk of Tallahassee, FL As Youth Advocate of the Year 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008 2Health News:A research on 'craving' for tobacco establishes the bases for addiction control 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: